Fig. 3

MaR1 inhibits inflammatory responses following hepatic I/R injury. Serum levels of cytokines IL-6 (a), IL-1β (b) and IL-10 (c) in WT mice after sham or I/R (1 h/6 h) treated with PBS or MaR1 (20 ng/mouse) (n = 6/gp). d Representative immunofluorescence staining of LY6G-positive inflammatory cells in ischemic lobes of mice in the indicated groups. Ly6G (white), nucleus (blue), and F-actin (green); (scale bar = 100 µm; original magnification ×40). e Quantification of infiltrating Ly6G-positive neutrophils; n = 3/gp. Western blot analysis of total and phosphorylated (p) ERK, JNK and p38 in liver after sham or I/R surgery (f) or primary mouse HC after H/R (g) with treatments as indicated. In vivo: n = 5/gp; 20 ng/mouse MaR1. In vitro: 100 nM MaR1 given as a pretreatment. Images representative of at least 3 independent experiments. Results are expressed as mean ± SEM. *P < 0.05